In July 2013, Mallinckrodt Pharmaceuticals became an independent, publicly traded, $2.1 billion company. We’re now driven by a new energy, led by highly motivated people and ready to build on a name that’s synonymous with quality, integrity and service. Behind us is over 145 years of growth and innovation. Ahead is a future that promises even more.
A market-leader in speciality pharmaceuticals and medical imaging, we develop, manufacture and market products that diagnose serious illnesses and treat pain. Our pharmaceuticals business encompasses branded and generic products as well as the Active Pharmaceuticals Ingredients used to make prescription drugs. Our imaging business focuses on contrast media and delivery systems plus nuclear medicine.
These product lines are a tremendous platform for international growth. Already a global healthcare leader, we plan to expand into emerging markets where we can add the most value and make a bigger difference to patients and customers. Together we will work tirelessly to find more imaginative ways to help more patients, accelerate product development and deliver long-term, above-market growth. – less